BX Swiss TOP 30 CHF
1.238,59
PKT
+3,16
PKT
+0,26
%
Werbung
Analysen zu BX Swiss TOP 30 CHF-Werten
Datum | Rating | Analyst | |
---|---|---|---|
19.01.23 | Roche Sell | Deutsche Bank AG | |
18.01.23 | Richemont Overweight | JP Morgan Chase & Co. | |
18.01.23 | Richemont Buy | Deutsche Bank AG | |
18.01.23 | Swiss Re Overweight | JP Morgan Chase & Co. | |
18.01.23 | Richemont Market-Perform | Bernstein Research | |
18.01.23 | Richemont Conviction Buy List | Goldman Sachs Group Inc. | |
18.01.23 | Richemont Buy | UBS AG | |
18.01.23 | Swiss Re Sell | Goldman Sachs Group Inc. | |
18.01.23 | Nestlé Hold | Jefferies & Company Inc. | |
17.01.23 | ABB (Asea Brown Boveri) Buy | UBS AG | |
17.01.23 | Richemont Outperform | RBC Capital Markets | |
17.01.23 | ABB (Asea Brown Boveri) Buy | Goldman Sachs Group Inc. | |
16.01.23 | ABB (Asea Brown Boveri) Outperform | RBC Capital Markets | |
16.01.23 | Zurich Insurance Neutral | Goldman Sachs Group Inc. | |
13.01.23 | Nestlé Buy | UBS AG | |
13.01.23 | UBS Underweight | Barclays Capital | |
13.01.23 | UBS Underweight | Barclays Capital | |
13.01.23 | UBS Hold | Deutsche Bank AG | |
13.01.23 | Zurich Insurance Hold | Jefferies & Company Inc. | |
13.01.23 | Zurich Insurance Overweight | JP Morgan Chase & Co. | |
12.01.23 | Zurich Insurance Buy | UBS AG | |
12.01.23 | Swiss Re Sell | UBS AG | |
12.01.23 | ABB (Asea Brown Boveri) Neutral | JP Morgan Chase & Co. | |
12.01.23 | Nestlé Buy | Deutsche Bank AG | |
12.01.23 | ABB (Asea Brown Boveri) Equal Weight | Barclays Capital | |
11.01.23 | UBS Neutral | UBS AG | |
11.01.23 | UBS Buy | Goldman Sachs Group Inc. | |
11.01.23 | Nestlé Buy | Goldman Sachs Group Inc. | |
10.01.23 | ABB (Asea Brown Boveri) Neutral | JP Morgan Chase & Co. | |
10.01.23 | Richemont Outperform | RBC Capital Markets | |
10.01.23 | Zurich Insurance Hold | Deutsche Bank AG | |
09.01.23 | Roche Neutral | UBS AG | |
09.01.23 | Novartis Neutral | UBS AG | |
09.01.23 | Richemont Buy | UBS AG | |
09.01.23 | Givaudan Underperform | Bernstein Research | |
07.01.23 | UBS Neutral | Credit Suisse Group | |
06.01.23 | Roche Outperform | Credit Suisse Group | |
06.01.23 | Novartis Underperform | Credit Suisse Group | |
06.01.23 | Novartis Underweight | Morgan Stanley | |
06.01.23 | UBS Outperform | RBC Capital Markets |